Interferon-γ Receptor Signaling in Dendritic Cells Restrains Spontaneous Proliferation of CD4+ T Cells in Chronic Lymphopenic Mice

by Laura Knop, Charlotte Frommer, Diana Stoycheva, Katrin Deiser, Ulrich Kalinke, Thomas Blankenstein, Thomas Blankenstein, Thomas Blankenstein, Thomas Kammertoens, Ildiko Rita Dunay, Thomas Schüler
Published 2019-02-01

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy

by Thomas Blankenstein, Natalia Plewa, Lucia Poncette
Published 2023-02-01

Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.

by Katrin Deiser, Diana Stoycheva, Ute Bank, Thomas Blankenstein, Thomas Schüler
Published 2016-01-01

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma

by Thomas Blankenstein, Lena Immisch, George Papafotiou, Oliver Popp, Philipp Mertins, Gerald Willimsky
Published 2022-10-01

SigsPack, a package for cancer mutational signatures

by Franziska Schumann, Eric Blanc, Clemens Messerschmidt, Thomas Blankenstein, Antonia Busse, Dieter Beule
Published 2019-09-01

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al

by Thomas Blankenstein, Lena Immisch, George Papafotiou, Oliver Popp, Philipp Mertins, Gerald Willimsky
Published 2023-03-01

225 Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs

by Matthias Leisegang, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Ioannis Gavvovidis
Published 2021-11-01

Identification and ranking of recurrent neo-epitopes in cancer

by Eric Blanc, Manuel Holtgrewe, Arunraj Dhamodaran, Clemens Messerschmidt, Gerald Willimsky, Thomas Blankenstein, Dieter Beule
Published 2019-11-01

Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors

by Lena Immisch, Lena Immisch, Lena Immisch, George Papafotiou, George Papafotiou, George Papafotiou, Nerea Gallarín Delgado, Vivian Scheuplein, Annette Paschen, Annette Paschen, Thomas Blankenstein, Thomas Blankenstein, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky
Published 2023-02-01

HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation

by Carlotta Welters, Marthe-Lina Welters, Serena Stadler, Lars Bullinger, Julian Strobel, Holger Hackstein, Arunraj Dhamodaran, Thomas Blankenstein, Leo Hansmann
Published 2023-09-01

In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo

by Gerald Willimsky, Christin Beier, Lena Immisch, George Papafotiou, Vivian Scheuplein, Andrean Goede, Hermann-Georg Holzhütter, Thomas Blankenstein, Peter M Kloetzel
Published 2021-04-01

95 MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy

by Ronald Simon, Thomas Blankenstein, Jennifer Oduro, Natalia Gorbokon, Christoph Fraune, Julia Bluhm, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo
Published 2021-11-01

Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires

by Corinna Grunert, Gerald Willimsky, Caroline Anna Peuker, Simone Rhein, Leo Hansmann, Thomas Blankenstein, Eric Blanc, Dieter Beule, Ulrich Keller, Antonio Pezzutto, Antonia Busse
Published 2022-04-01

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.

by Armin Gerbitz, Madhusudhanan Sukumar, Florian Helm, Andrea Wilke, Christian Friese, Cornelia Fahrenwaldt, Frank M Lehmann, Christoph Loddenkemper, Thomas Kammertoens, Josef Mautner, Clemens A Schmitt, Thomas Blankenstein, Georg W Bornkamm
Published 2012-01-01

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer

by Livius Penter, Kerstin Dietze, Julia Ritter, Maria Fernanda Lammoglia Cobo, Josefin Garmshausen, Felix Aigner, Lars Bullinger, Holger Hackstein, Sandra Wienzek-Lischka, Thomas Blankenstein, Michael Hummel, Klaus Dornmair, Leo Hansmann
Published 2019-06-01

499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial)

by Fiona Thistlethwaite, Sylvie Rottey, Emiliano Calvo, Antonia Busse, Martin Wermke, Ralf Wolter, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo, Ioannis Gavvovidis, Marie-Luise Goebeler, Nuria Kotecki, Carolina Perdomo-Ortiz
Published 2021-11-01

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus

by Ana Textor, Laura Grunewald, Kathleen Anders, Anika Klaus, Silke Schwiebert, Annika Winkler, Maria Stecklum, Jana Rolff, Anton G. Henssen, Uta E. Höpken, Angelika Eggert, Johannes H. Schulte, Michael C. Jensen, Thomas Blankenstein, Annette Künkele
Published 2021-03-01